Gilead Sciences (GILD) Aandeel Koers
Gilead Sciences Koers
In de afgelopen 19 jaar liet Gilead Sciences de omzet jaarlijks met 12,7% groeien tot 29,44 Miljard USD. De winst per aandeel is de afgelopen 18 jaar met 12,1% per jaar gegroeid. Bij Gilead Sciences is de nettowinstmarge met 28,9% ten opzichte van 22,8% enkele jaren geleden gestegen. Op de huidige koers komt het dividendrendement uit op ongeveer 1,81%. De uitkeringsratio ligt rond 47% van de winst. Het dividend is de afgelopen 10 jaar met 9,4% per jaar gegroeid. Het consensus-koersdoel voor Gilead Sciences op 12 maanden bedraagt 155,00 USD, circa 11,2% onder de huidige koers. Van de 36 analisten geven 30 het aandeel een koopadvies — per saldo een Kopen-consensus.
Gilead Sciences aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Gilead Sciences bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company with a diversified business model. Its primary focus is on the research, development, and commercialization of innovative medications to treat and prevent life-threatening diseases. Gilead operates in multiple therapeutic areas, including HIV/AIDS, liver diseases, hematology/oncology, respiratory, cardiovascular, and viral infections. The company's business model revolves around discovering and designing new drugs, conducting clinical trials, obtaining regulatory approvals, manufacturing, marketing, and distribution of its pharmaceutical products. Through strategic collaborations and acquisitions, Gilead continuously expands its portfolio and aims to improve the quality of life for patients worldwide.
Gilead Sciences Inc is primarily active in the pharmaceutical industry.
The main competitors of Gilead Sciences Inc in the market include renowned companies like AbbVie, Bristol-Myers Squibb, and Merck & Co. These pharmaceutical giants operate in similar therapeutic areas and engage in the research, development, and commercialization of innovative medicines. At present, Gilead Sciences Inc faces competition in the fields of antiviral drugs, liver diseases, HIV/AIDS treatments, and oncology from these prominent industry players.
Gilead Sciences Inc, a leading biopharmaceutical company, was founded in 1987 by Dr. Michael L. Riordan in Foster City, California, USA. It specializes in discovering, developing, and commercializing innovative medicines to address unmet medical needs. Gilead has a rich history of pioneering breakthrough treatments for critical diseases such as HIV/AIDS, hepatitis, and other viral infections. With a mission to advance patient care globally, Gilead has expanded its portfolio through strategic acquisitions and collaborations, constantly striving to improve and save lives. Today, Gilead Sciences Inc remains committed to research, development, and manufacturing of transformative therapies across various therapeutic areas.
Gilead Sciences Inc has achieved several significant milestones throughout its history. It gained global recognition with the development of groundbreaking antiviral drugs such as Sovaldi and Harvoni, revolutionizing the treatment of hepatitis C. The company also made remarkable progress in the field of HIV, introducing a single-tablet regimen named Genvoya, providing convenient and effective therapy. Gilead Sciences Inc further expanded its therapeutic areas, bringing forth innovative treatments for life-threatening diseases like cancer and autoimmune disorders. Moreover, it received approval for its antiviral drug, remdesivir, as a treatment for COVID-19. These milestones solidify Gilead Sciences Inc's position as a leader in the pharmaceutical industry.
Gilead Sciences Inc is primarily present in various countries and regions worldwide. Some key locations where the company has a strong presence include the United States, Europe (including countries like Germany, France, and the United Kingdom), Asia-Pacific (including countries like Japan, Australia, and China), and Latin America (including countries like Brazil and Mexico). With a global footprint, Gilead Sciences Inc operates in multiple markets, providing its innovative biopharmaceutical products and therapies to patients across different continents.
Gilead Sciences Inc represents a commitment to improving the lives of patients through innovative research and development in the fields of life sciences and biotechnology. Their corporate philosophy emphasizes a patient-centered approach, scientific integrity, and a drive to address unmet medical needs. Gilead Sciences Inc focuses on developing breakthrough therapies and treatments to combat diseases such as HIV/AIDS, viral hepatitis, and other challenging illnesses. They prioritize collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality healthcare solutions. With a strong emphasis on scientific excellence and a dedication to addressing global health challenges, Gilead Sciences Inc continues to make a significant impact in the industry.
Analisten hanteren momenteel een gemiddeld koersdoel van 153,33 USD voor het aandeel Gilead Sciences (mediaan: 155,00 USD), oftewel -12,1 % ten opzichte van de laatste koers. De consensus is gebaseerd op 36 analistenratings.
36 analisten beoordelen het aandeel Gilead Sciences momenteel: 30 adviseren kopen, 6 houden en 0 verkopen. Voor 2026 verwachten analisten dat Gilead Sciences een omzet van 30,78 Miljard USD en winst per aandeel van -0,40 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Gilead Sciences op 155,37 EUR (174,48 USD).
Het aandeel Gilead Sciences (GILD) is genoteerd aan 10 beurzen, waaronder: NASDAQ (GILD), London (0QYQ.L), SIX (Zürich) (GILD.SW), XETRA (GIS.DE), Frankfurt (GIS.F), München (GIS.MU), Düsseldorf (GIS.DU), Hamburg (GIS.HM).
Gilead Sciences Inc is a biopharmaceutical company that develops innovative therapies for serious diseases such as HIV, hepatitis B and C, cancer, lung and liver diseases. The company is headquartered in Foster City, California and has been publicly traded since 1987. Gilead operates worldwide and has offices in more than 30 countries. The business model of Gilead Sciences is based on the development, manufacturing and marketing of innovative drugs. The company specializes in discovering chemicals that enable effective treatment of diseases. In recent years, Gilead Sciences has focused on the development of drugs for hepatitis C and HIV, which has contributed to significant revenue growth. Gilead Sciences' products are divided into three divisions: 1. Infectious Diseases: This division includes drugs for the treatment of HIV, hepatitis B and C, and other infectious diseases. The most well-known and successful drug is Viread, used for the treatment of HIV and hepatitis B. Another promising drug is Harvoni, a combination of two active ingredients used to treat hepatitis C. 2. Oncology: This division includes drugs for the treatment of various types of cancer, such as multiple myeloma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The most well-known drug is Revlimid, used for the treatment of multiple myeloma and other types of cancer. 3. Inflammatory and respiratory diseases: This division includes drugs for the treatment of conditions such as rheumatoid arthritis, Crohn's disease, and emphysema. The most well-known drug is Remicade, used for the treatment of inflammatory bowel disease. In recent years, Gilead Sciences has established itself as a leading biopharmaceutical company through significant acquisitions and acquisitions. For example, in 2017, Kite Pharma, a company specializing in cancer immunotherapy, was acquired for $11.9 billion. This acquisition allowed Gilead Sciences to expand its portfolio of oncology drugs and strengthen its market position. Gilead Sciences' business model is based on a strong research and development department that continuously discovers and introduces new drugs to the market. Gilead Sciences has a broad pipeline of drugs in development to provide effective treatment for serious diseases to patients worldwide. The company works closely with regulatory authorities to expedite the approval of new drugs. Overall, Gilead Sciences Inc is an innovative and successful biopharmaceutical company specializing in the development and marketing of drugs for the treatment of serious diseases. The company has established itself as a leading provider in this field in recent years and will continue to play a crucial role in the development of new therapies in the future.
De verwachte omzet van Gilead Sciences bedraagt 30,78 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Gilead Sciences bedraagt -500,02 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Gilead Sciences bedraagt momenteel -437,23. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Gilead Sciences-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Gilead Sciences bedraagt momenteel 7,10. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Gilead Sciences-aandeel.
De Eulerpool Kwaliteitsscore voor Gilead Sciences is 5/10.
De ISIN van Gilead Sciences is US3755581036. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Gilead Sciences is 885823. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Gilead Sciences is GILD. Onder dit beurstickersymbool wordt het Gilead Sciences-aandeel op de beurs verhandeld.
Gilead Sciences aandeel
Gilead Sciences Peer Group
Gilead Sciences Ticker
Gilead Sciences FIGI
Alle fundamentals en diepgaande analyse van Gilead Sciences
Onze aandelenanalyse van het Gilead Sciences-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Gilead Sciences. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: